SCHEMBL26640303

SCHEMBL26640303

CC(C)(O)CN1Cc2ccc(Nc3ncc4c(n3)CN(C(=O)OC(C)(C)C)CC4)cc2C1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.57
▸ IGF1R P08069 1/20 0.46
▸ CHEK1 O14757 12/20 0.46
▸ FLT3 P36888 12/20 0.46
▸ JAK2 O60674 3/20 0.44
▸ JAK3 P52333 3/20 0.44
▸ PTK2 Q05397 3/20 0.44
▸ ESR2 Q92731 1/20 0.44
▸ WEE1 P30291 1/20 0.43
▸ NR1H2 P55055 1/20 0.43
▸ KIT P10721 2/20 0.43
▸ MAP3K7 O43318 1/20 0.43
▸ RPS6KB1 P23443 1/20 0.43
▸ PRKAG1 P54619 1/20 0.43
▸ PRKAA2 P54646 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ PRKAB1 Q9Y478 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26640456 0.89 MAPT (0.64) MAPTIGF1RCHEK1FLT3JAK2
SCHEMBL26640202 0.86 MAPT (0.62) MAPTIGF1RJAK2JAK3PTK2
SCHEMBL26640600 0.84 MAPT (0.61) MAPTIGF1RJAK2JAK3PTK2
SCHEMBL30648622 0.84 MAPT (0.61) MAPTIGF1RJAK2JAK3PTK2
SCHEMBL27053860 0.83 MAPT (0.60) MAPTIGF1RJAK2JAK3PTK2
SCHEMBL27054345 0.82 MAPT (0.56) MAPTIGF1RJAK2JAK3PTK2
SCHEMBL26640513 0.82 MAPT (0.58) MAPTIGF1RCHEK1FLT3JAK2
SCHEMBL26640688 0.81 MAPT (0.66) MAPTJAK3
SCHEMBL26640159 0.81 MAPT (0.59) MAPTIGF1RCHEK1FLT3JAK2
SCHEMBL30648732 0.81 MAPT (0.58) MAPTJAK2JAK3PTK2ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 — — EP disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 MAPT 3283/4885IGF1R 3949/4885CHEK1 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback